Search Results - "Meerten, Esther"

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence by Ham, Janneke C., Meerten, Esther, Fiets, W. Edward, Beerepoot, Laurens V., Jeurissen, Frank J. F., Slingerland, Marije, Jonker, Marianne A., Husson, Olga, Graaf, Winette T. A., Herpen, Carla M. L.

“…Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) has limited progression‐free survival (PFS)…”
Get full text

Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable by Bugter, Oisín, Iwaarden, Dirk L.P., Dronkers, Emilie A.C., Herdt, Martine J., Wieringa, Marjan H., Verduijn, Gerda M., Mureau, Marc A.M., Hove, Ivo, Meerten, Esther, Hardillo, José A., Baatenburg de Jong, Robert J.

“…Background The objectives of this study are to determine the incidence and survival rate of patients with head and neck squamous cell carcinoma (HNSCC) with…”
Get full text

Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area by Meerten, Esther, Franckena, Martine, Wiemer, Erik, Doorn, Lena, Kraan, Jaco, Westermann, Anneke, Sleijfer, Stefan

“…Background. Patients with recurrent cervical cancer in a previously irradiated area might benefit from cisplatin combined with hyperthermia. Lapatinib inhibits…”
Get full text

Intraoperative Radiation Therapy Reduces Local Recurrence Rates in Patients With Microscopically Involved Circumferential Resection Margins After Resection of Locally Advanced Rectal Cancer by Alberda, Wijnand J., MD, Verhoef, Cornelis, MD, PhD, Nuyttens, Joost J., MD PhD, van Meerten, Esther, MD, PhD, Rothbarth, Joost, MD, PhD, de Wilt, Johannes H.W., MD, PhD, Burger, Jacobus W.A., MD, PhD

“…Purpose Intraoperative radiation therapy (IORT) is advocated by some for patients with locally advanced rectal cancer (LARC) who have involved or narrow…”
Get full text

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer by Gootjes, Elske C., Stok, Eric P., Buffart, Tineke E., Bakkerus, Lotte, Labots, Mariette, Zonderhuis, Barbara M., Tuynman, Jurriaan B., Meijerink, Martijn R., Ven, Peter M., Haasbeek, Cornelis J.A., ten Tije, Albert J., Groot, Jan‐Willem B., Hendriks, Mathijs P., Meerten, Esther, Nuyttens, Joost J.M.E., Grunhagen, Dirk J., Verhoef, Cornelis, Verheul, Henk M.W.

“…Introduction Local treatment of metastases is frequently performed in patients with multiorgan metastatic colorectal carcinoma (mCRC) analogous to selected…”
Get full text

Quality of Life During Neoadjuvant Treatment and After Surgery for Resectable Esophageal Carcinoma by van Meerten, Esther, M.D, van der Gaast, Ate, M.D., Ph.D, Looman, Caspar W.N., M.Sc, Tilanus, Hugo W.G., M.D., Ph.D, Muller, Karin, M.D, Essink-Bot, Marie-Louise, M.D., Ph.D

“…Purpose Because of the trade-off between the potentially negative quality-of-life (QoL) effects and uncertain favorable survival effect of neoadjuvant…”
Get full text

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine by de Man, Femke M., Veerman, G.D. Marijn, Oomen-de Hoop, Esther, Deenen, Maarten J., Meulendijks, Didier, Mandigers, Caroline M.P.W., Soesan, Marcel, Schellens, Jan H.M., van Meerten, Esther, van Gelder, Teun, Mathijssen, Ron H.J.

“…Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative…”
Get full text

Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis by Schoonbeek, Rosanne C., de Jel, Dominique V.C., van Dijk, Boukje A.C., Willems, Stefan M., Bloemena, Elisabeth, Hoebers, Frank J.P., van Meerten, Esther, Verbist, Berit M., Smeele, Ludi E., Halmos, György B., Merkx, Matthias A.W., Siesling, Sabine, De Bree, Remco, Takes, Robert P.

“…•The head and neck cancer incidence was nearly 25% less during the first COVID wave.•The lower incidence was mainly observed in oral cavity and laryngeal…”
Get full text

HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial by Elbers, Joris B W, Gunsch, Pascal A, Debets, Reno, Keereweer, Stijn, van Meerten, Esther, Zindler, Jaap, van Norden, Yvette, Hoogeman, Mischa S, Verduijn, Gerda M, Kroesen, Michiel, Nout, Remi A

“…Radiotherapy (RT) is the standard of care for most advanced head and neck squamous cell carcinoma (HNSCC) and results in an unfavorable 5-year overall survival…”
Get full text

Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial by de Boer, Nadine Leonie, Brandt-Kerkhof, Alexandra R M, Madsen, Eva V E, Diepeveen, Marjolein, van Meerten, Esther, van Eerden, Ruben A G, de Man, Femke M, Bouamar, Rachida, Koolen, Stijn L W, de Hingh, Ignace H J T, Bakkers, Checca, Rovers, Koen P, Creemers, Geert-Jan M, Deenen, Maarten J, Kranenburg, Onno W, Constantinides, Alexander, Mathijssen, Ron H J, Verhoef, Cornelis, Burger, Jacobus W A

“…IntroductionCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard of care for patients with peritoneal metastases…”
Get full text

Systemic treatment for oesophageal cancer by Meerten, Esther van, van der Gaast, Ate

“…Oesophageal cancer, in particular adenocarcinomas, has shown a rapid and largely unexplained increase in incidence in the Western world. Despite advances in…”
Get full text

Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study) by Driessen, Chantal M, Ham, Janneke C, Te Loo, Maroeska, van Meerten, Esther, van Lamoen, Maurits, Hakobjan, Marina H, Takes, Robert P, van der Graaf, Winette T, Kaanders, Johannes H, Coenen, Marieke J H, van Herpen, Carla M

“…Ototoxicity and nephrotoxicity are potentially irreversible side effects of chemoradiotherapy with cisplatin in locally advanced head and neck cancer (LAHNC)…”
Get full text

Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury by Klumpers, Marije J., Witte, Ward De, Gattuso, Giovanna, Schiavello, Elisabetta, Terenziani, Monica, Massimino, Maura, Gidding, Corrie E. M., Vermeulen, Sita H., Driessen, Chantal M., Van Herpen, Carla M., Van Meerten, Esther, Guchelaar, Henk-Jan, Coenen, Marieke J. H., Te Loo, D. Maroeska W. M.

“…Nephrotoxicity is a common and dose-limiting side effect of platinum compounds, which often manifests as acute kidney injury or hypomagnesemia. This study…”
Get full text

Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life by Keereweer, Stijn, Kerrebijn, Jeroen D. F., Al-Mamgani, Abrahim, Sewnaik, Aniel, de Jong, Robert J. Baatenburg, van Meerten, Esther

“…Chemoradiation (CRT) is a valuable treatment option for advanced hypopharyngeal squamous cell cancer (HSCC). However, long-term toxicity and quality of life…”
Get full text

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study by van der Bol, Jessica M, Loos, Walter J, de Jong, Floris A, van Meerten, Esther, Konings, Inge R.H.M, Lam, Mei H, de Bruijn, Peter, Wiemer, Erik A.C, Verweij, Jaap, Mathijssen, Ron H.J

“…Abstract Background Omeprazole is one of the most prescribed medications worldwide and within the class of proton pump inhibitors, it is most frequently…”
Get full text

Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study by Stijns, Rutger C H, de Graaf, Eelco J R, Punt, Cornelis J A, Nagtegaal, Iris D, Nuyttens, Joost J M E, van Meerten, Esther, Tanis, Pieter J, de Hingh, Ignace H J T, van der Schelling, George P, Acherman, Yair, Leijtens, Jeroen W A, Bremers, Andreas J A, Beets, Geerard L, Hoff, Christiaan, Verhoef, Cornelis, Marijnen, Corrie A M, de Wilt, Johannes H W

“…Treatment of rectal cancer is shifting toward organ preservation aiming to reduce surgery-related morbidity. Short-term outcomes of organ-preserving strategies…”
Get more information

Treatment and Survival Outcomes of Patients with Colorectal Peritoneal Metastases deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) by Dietz, Michelle, Ziekman, Merijn, Job van kooten, Brandt-Kerkhof, Alexandra, van Meerten, Esther, Verhoef, Kees, Madsen, Eva

Get full text

Prognostic factors for severe diarrhea in patients with locally advanced rectal carcinoma treated with neoadjuvant chemoradiation with capecitabine: A single-center cohort study by Hartman, Wesley, De Hoop, Esther Oomen, Verhoef, Cornelis, Nuyttens, Joost, van Meerten, Esther

“…Abstract only e15176 Background: Chemoradiation with concomitant capecitabine (CRT) followed by total mesorectal excision is the standard of care for locally…”
Get full text

A comprehensive approach to defining the cutoff value of oligometastasis in head and neck squamous cell carcinoma by Berzenji, Diako, Oude Booijink, Olivier R. G., Gahrmann, Renske, Mast, Hetty, Capala, Marta E., Koppes, Sjors A., van Meerten, Esther, Kremer, Bernd, Baatenburg de Jong, Robert Jan, Offerman, Marinella P. J., Hardillo, Jose A.

“…Abstract Background Patients with limited distant metastatic disease, also known as oligometastasis, show better survival rates than polymetastatic patients,…”
Get full text

Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment by Verduijn, Gerda M., Sijtsema, Nienke D., van Norden, Yvette, Heemsbergen, Wilma D., Mast, Hetty, Sewnaik, Aniel, Chin, Denzel, Baker, Sarah, Capala, Marta E., van der Lugt, Aad, van Meerten, Esther, Hoogeman, Mischa S., Petit, Steven F.

“…•Interest in hypofractionated radiotherapy with more heterogeneous dose distributions is increasing.•Existing osteoradionecrosis (ORN) risk models cannot be…”
Get full text